Get the Stockscreener App
46.05
3.30%
-1.56
Omnicell Inc stock is traded at $46.05, with a volume of 169.58K.
It is down -3.30% in the last 24 hours and down -5.41% over the past month.
Omnicell Inc provides automation and business analytics software for healthcare providers. It helps its customers to define and deliver cost-effective medication management that is designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks, and to drive improved clinical, operational, and financial outcomes across all care settings. Omnicell generates the vast majority of its revenue in the United States.
See More
Previous Close:
$47.60
Open:
$47.29
24h Volume:
169.58K
Relative Volume:
0.31
Market Cap:
$2.11B
Revenue:
$1.08B
Net Income/Loss:
$-20.76M
P/E Ratio:
-59.80
EPS:
-0.77
Net Cash Flow:
$151.63M
1W Performance:
+1.29%
1M Performance:
-5.41%
6M Performance:
+45.64%
1Y Performance:
+36.24%
1-Day Range:
$45.76
$47.37
1-Week Range:
$44.87
$48.67
52-Week Range:
$25.12
$55.74
Omnicell Inc Stock (OMCL) Company Profile
Name
Omnicell Inc
Sector
Industry
Phone
(877) 415-9990
Address
4220 NORTH FREEWAY, FORT WORTH
Compare OMCL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OMCL
Omnicell Inc
|
46.05 | 2.11B | 1.08B | -20.76M | 151.63M | -0.46 |
|
VEEV
Veeva Systems Inc
|
227.47 | 36.83B | 2.57B | 615.26M | 996.76M | 3.75 |
|
SOLV
Solventum Corp
|
70.12 | 12.44B | 8.26B | 66.00M | 1.17B | 0.3682 |
|
TEM
Tempus Ai Inc
|
57.02 | 10.38B | 640.44M | -743.28M | -206.93M | -11.29 |
|
DOCS
Doximity Inc
|
53.74 | 9.97B | 493.63M | 160.55M | 162.20M | 0.80 |
|
HQY
Healthequity Inc
|
102.11 | 8.71B | 1.10B | 105.67M | -197.98M | 1.20 |
Omnicell Inc Stock (OMCL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-31-24 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-02-24 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-03-24 | Initiated | Barclays | Underweight |
| Nov-03-23 | Downgrade | BTIG Research | Buy → Neutral |
| Nov-03-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-03-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-11-23 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Sep-26-23 | Reiterated | Wells Fargo | Underweight |
| Aug-02-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-20-23 | Downgrade | Wells Fargo | Overweight → Underweight |
| Feb-27-23 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-03-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Sep-16-22 | Initiated | KeyBanc Capital Markets | Overweight |
| Sep-09-22 | Initiated | BofA Securities | Buy |
| Jul-15-22 | Initiated | SVB Leerink | Mkt Perform |
| Dec-06-21 | Resumed | Wells Fargo | Overweight |
| Jun-09-21 | Initiated | JP Morgan | Neutral |
| May-24-21 | Initiated | BTIG Research | Buy |
| Feb-02-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-08-20 | Initiated | Berenberg | Buy |
| Dec-03-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-07-20 | Initiated | Stephens | Overweight |
| Feb-07-20 | Reiterated | Dougherty & Company | Buy |
| Nov-21-19 | Reiterated | Dougherty & Company | Buy |
| Jul-26-19 | Upgrade | Craig Hallum | Hold → Buy |
| Mar-07-19 | Reiterated | Dougherty & Company | Buy |
| Jun-29-18 | Resumed | The Benchmark Company | Buy |
| Sep-05-17 | Reiterated | The Benchmark Company | Buy |
| Jul-28-17 | Reiterated | Dougherty & Company | Buy |
| Apr-21-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jan-19-17 | Initiated | Dougherty & Company | Buy |
| Dec-06-16 | Reiterated | The Benchmark Company | Buy |
| Jul-07-16 | Reiterated | FBR Capital | Outperform |
| Mar-21-16 | Reiterated | Topeka Capital Markets | Buy |
| Jan-07-16 | Initiated | The Benchmark Company | Buy |
| Nov-16-15 | Reiterated | Topeka Capital Markets | Buy |
| Oct-30-15 | Reiterated | FBR Capital | Outperform |
| Sep-28-15 | Upgrade | Sidoti | Neutral → Buy |
| Jul-31-15 | Reiterated | Topeka Capital Markets | Buy |
View All
Omnicell Inc Stock (OMCL) Latest News
Rockefeller Capital Management L.P. Acquires 16,116 Shares of Omnicell, Inc. (NASDAQ:OMCL) - MarketBeat
Bellevue Group AG Sells 37,658 Shares of Omnicell, Inc. (NASDAQ:OMCL) - MarketBeat
Why Is Omnicell (OMCL) Down 0.4% Since Last Earnings Report? - MSN
Omnicell (NASDAQ:OMCL) Stock Price Down 3.7%Time to Sell? - MarketBeat
Dynamic Technology Lab Private Ltd Sells 15,351 Shares of Omnicell, Inc. (NASDAQ:OMCL) - MarketBeat
OMCL (Omnicell) PE Ratio without NRI : 32.58 (As of Nov. 30, 2024) - GuruFocus.com
Algert Global LLC Has $718,000 Stock Position in Omnicell, Inc. (NASDAQ:OMCL) - MarketBeat
Intech Investment Management LLC Takes $753,000 Position in Omnicell, Inc. (NASDAQ:OMCL) - MarketBeat
Should You Investigate Omnicell, Inc. (NASDAQ:OMCL) At US$48.46? - Yahoo Finance
Little Excitement Around Omnicell, Inc.'s (NASDAQ:OMCL) Revenues - Simply Wall St
Millrace Asset Group Inc. Invests $1.22 Million in Omnicell, Inc. (NASDAQ:OMCL) - MarketBeat
Advantage Alpha Capital Partners LP Sells 24,485 Shares of Omnicell, Inc. (NASDAQ:OMCL) - MarketBeat
Central Fill Pharmacy Automation Market Future Business - openPR
Omnicell's SWOT analysis: healthcare tech stock navigates market shifts - Investing.com
Omnicell's SWOT analysis: healthcare tech stock navigates market shifts By Investing.com - Investing.com Canada
Global Surgery Management Software Market Size, Share - openPR
Pharmacy Automation System Market to Hit $11.21 Billion by 2030 | Becton, Dickinson and Company, Omnicell, - EIN News
Wall Street Analysts Believe Omnicell (OMCL) Could Rally 26.73%: Here's is How to Trade - MSN
Omnicell price target raised to $44 from $37 at JPMorgan - MSN
Omnicell to Present at the Piper Sandler 36th Annual Healthcare Conference - Business Wire
Pacer Advisors Inc. Has $54.35 Million Stake in Omnicell, Inc. (NASDAQ:OMCL) - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Buys 259,463 Shares of Omnicell, Inc. (NASDAQ:OMCL) - MarketBeat
OMCL (Omnicell) Cash From Other Investing Activities : $0 Mil (TTM As of Sep. 2024) - GuruFocus.com
OMCL (Omnicell) Cyclically Adjusted PS Ratio : 1.74 (As of Nov. 21, 2024) - GuruFocus.com
Beyond The Numbers: 6 Analysts Discuss Omnicell Stock - Benzinga
Brown Capital Management LLC Reduces Stock Position in Omnicell, Inc. (NASDAQ:OMCL) - MarketBeat
Here's Why You Should Add OMCL Stock to Your Portfolio Now - MSN
Royce & Associates LP Purchases New Holdings in Omnicell, Inc. (NASDAQ:OMCL) - MarketBeat
JPMorgan raises Omnicell target to $44, maintains neutral stance By Investing.com - Investing.com Canada
Omnicell prices $150M debt offering via issuance of convertible senior notes - MSN
Omnicell Prices $150M Convertible Notes at 1% Interest, Due 2029 | OMCL Stock News - StockTitan
Robotic Dentistry Market: Trade Analysis and Growth - openPR
Omnicell Announces Pricing of $150 Million Convertible Senior Notes Offering - Business Wire
Omnicell (NASDAQ:OMCL) Shares Gap DownHere's What Happened - MarketBeat
The Top 100 Healthcare Technology Companies of 2024 - The Healthcare Technology Report.
Medication Management Systems Market Will Accelerate Rapidly - openPR
Principal Financial Group Inc. Sells 31,062 Shares of Omnicell, Inc. (NASDAQ:OMCL) - MarketBeat
Omnicell Announces Proposed Private Placement of $150 Million of Convertible Senior Notes - BioSpace
Omnicell announces $150 million convertible notes offering - Investing.com
What is Zacks Research's Estimate for Omnicell Q1 Earnings? - MarketBeat
Sumitomo Mitsui Trust Group Inc. Acquires New Shares in Omnicell, Inc. (NASDAQ:OMCL) - MarketBeat
Omnicell (NASDAQ:OMCL) Downgraded to "Hold" Rating by StockNews.com - MarketBeat
Victory Capital Management Inc. Raises Stake in Omnicell, Inc. (NASDAQ:OMCL) - MarketBeat
Better Than Expected Q2 Earnings Prompt Buying Interest In Omnicell - RTTNews
Omnicell, Inc. (NASDAQ:OMCL) Given Average Rating of "Hold" by Analysts - MarketBeat
Omnicell Inc. (OMCL) Quarterly 10-Q Report - Quartzy
New Horizons in Medication Management Tools Market Exploring - openPR
Surging Earnings Estimates Signal Upside for Omnicell (OMCL) Stock - MSN
Omnicell, Inc. (NASDAQ:OMCL) Q3 2024 Earnings Call Transcript - MSN
Omnicell's SWOT analysis: healthcare tech firm's stock rides upgrade wave By Investing.com - Investing.com Australia
Omnicell's SWOT analysis: healthcare tech firm's stock rides upgrade wave - Investing.com India
Omnicell Inc Stock (OMCL) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.18%
3.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):